TY - JOUR
T1 - Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes
T2 - A post hoc analysis from the REWIND randomized trial
AU - Raubenheimer, Peter J.
AU - Cushman, William C.
AU - Avezum, Alvaro
AU - Basile, Jan
AU - Conget, Ignacio
AU - Dagenais, Gilles
AU - Hoover, Anastasia
AU - Jansky, Petr
AU - Lanas, Fernando
AU - Leiter, Lawrence A.
AU - Lopez-Jaramillo, Patricio
AU - Pogosova, Nana
AU - Probstfield, Jeffrey
AU - Rao-Melacini, Purnima
AU - Rydén, Lars
AU - Sheu, Wayne H.H.
AU - Temelkova-Kurktschiev, Theodora
AU - C. Gerstein, Hertzel
N1 - Publisher Copyright:
© 2022 John Wiley & Sons Ltd.
PY - 2022/4
Y1 - 2022/4
N2 - Aim: To assess the occurrence of atrial fibrillation or atrial flutter (atrial arrhythmias [AA]) in patients with type 2 diabetes treated with once-weekly subcutaneous dulaglutide versus placebo. Materials and Methods: Patients without electrocardiographic (ECG)-confirmed AA at baseline and randomized in the REWIND trial were assessed for the development of AA based on an annual ECG. Additional analyses included whether dulaglutide compared with placebo reduced the composite outcome of AA or death, AA or cardiovascular death, AA or stroke and AA or heart failure. Results: Among 9543 participants (mean age 66 ± 7 years, with cardiovascular risk factors and 31% with previous cardiovascular disease) without AA at entry in the trial, 524 patients (5.5%) had at least one episode of AA during the median 5.4 years of follow-up. Incident AA occurred in 269 of the 4769 participants allocated to dulaglutide (5.6%), at a rate of 10.7 per 1000 person-years, versus 255 of the 4774 allocated to placebo (5.3%), at a rate of 10.5 per 1000 person-years (P =.59). There was also no effect of dulaglutide on the composite outcome of AA and death or AA and heart failure. Conclusion: This post hoc analysis of data from the REWIND trial showed that treatment with dulaglutide was not associated with a reduced incidence of AA in this at-risk group of patients with type 2 diabetes.
AB - Aim: To assess the occurrence of atrial fibrillation or atrial flutter (atrial arrhythmias [AA]) in patients with type 2 diabetes treated with once-weekly subcutaneous dulaglutide versus placebo. Materials and Methods: Patients without electrocardiographic (ECG)-confirmed AA at baseline and randomized in the REWIND trial were assessed for the development of AA based on an annual ECG. Additional analyses included whether dulaglutide compared with placebo reduced the composite outcome of AA or death, AA or cardiovascular death, AA or stroke and AA or heart failure. Results: Among 9543 participants (mean age 66 ± 7 years, with cardiovascular risk factors and 31% with previous cardiovascular disease) without AA at entry in the trial, 524 patients (5.5%) had at least one episode of AA during the median 5.4 years of follow-up. Incident AA occurred in 269 of the 4769 participants allocated to dulaglutide (5.6%), at a rate of 10.7 per 1000 person-years, versus 255 of the 4774 allocated to placebo (5.3%), at a rate of 10.5 per 1000 person-years (P =.59). There was also no effect of dulaglutide on the composite outcome of AA and death or AA and heart failure. Conclusion: This post hoc analysis of data from the REWIND trial showed that treatment with dulaglutide was not associated with a reduced incidence of AA in this at-risk group of patients with type 2 diabetes.
KW - atrial fibrillation
KW - atrial flutter
KW - dulaglutide
KW - glucagon-like peptide-1 receptor agonists
KW - type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85123496387&partnerID=8YFLogxK
U2 - 10.1111/dom.14634
DO - 10.1111/dom.14634
M3 - Artículo Científico
C2 - 34984808
AN - SCOPUS:85123496387
SN - 1462-8902
VL - 24
SP - 704
EP - 712
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
IS - 4
ER -
